MaxCyte director receives RSU and option grants
Hemrajani Rekha reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Hemrajani Rekha reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director Rekha Hemrajani reported equity awards consisting of restricted stock units and stock options. She received 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with a strike price of $1.13 per share, expiring on June 16, 2036. The annual grant for non-employee directors vests on June 17, 2027, subject to her continuous service, bringing her direct common stock holdings to 70,314 shares.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
2 txns
Insider
Hemrajani Rekha
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 49,579 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,421 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 49,579 contracts (Direct);
Common Stock — 70,314 shares (Direct)
Footnotes (2)
- F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
Key Figures
Restricted stock units granted: 30,421 RSUs
Stock options granted: 49,579 options
Option exercise price: $1.13 per share
+3 more
6 metrics
Restricted stock units granted
30,421 RSUs
Annual grant to non-employee director on June 17, 2026
Stock options granted
49,579 options
Stock Option (right to buy) granted on June 17, 2026
Option exercise price
$1.13 per share
Conversion or exercise price for 49,579 options
Option expiration date
June 16, 2036
Expiration for stock option grant
Shares underlying options
49,579 shares
Underlying common stock for option grant
Shares held after transaction
70,314 shares
Total direct common stock holdings after awards
Key Terms
restricted stock units ("RSUs"), Equity Grant Policy, non-employee directors, Stock Option (right to buy)
4 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Equity Grant Policy financial
"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."
non-employee directors financial
"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
Stock Option (right to buy) financial
"Stock Option (right to buy) with 49,579.0000 derivative shares was granted."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MaxCyte (MXCT) director Rekha Hemrajani report?
Director Rekha Hemrajani reported equity awards from MaxCyte, Inc. She acquired 30,421 restricted stock units and 49,579 stock options as part of her annual non-employee director compensation grant, increasing her direct common stock holdings to 70,314 shares after the award.
How many RSUs did Rekha Hemrajani receive from MaxCyte (MXCT)?
She received 30,421 restricted stock units from MaxCyte. Each RSU represents a contingent right to receive one share of the company’s common stock, subject to vesting conditions tied to her continued service as a non-employee director on the board.
What are the terms of Rekha Hemrajani’s MaxCyte (MXCT) stock option grant?
She was granted 49,579 stock options with a conversion or exercise price of $1.13 per share. These options relate to an equivalent number of common shares and are scheduled to expire on June 16, 2036, providing long-term equity exposure.
When do Rekha Hemrajani’s MaxCyte (MXCT) director equity awards vest?
The annual equity grant for the MaxCyte non-employee director vests on June 17, 2027. Vesting is conditioned on Rekha Hemrajani’s continuous service as of that date, covering both the restricted stock units and the stock option components of the award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
